Canbridge confirms ligand CD95 in Chinese patient biomarker study

By Shannon Ellis, Staff Writer ©2016. REPRINTED WITH PERMISSION FROM THOMSON REUTERS. SHANGHAI – Canbridge Life Sciences Inc. has confi rmed the existence of ligand CD95 in Chinese glioblastoma patients after completing the fi rst such biomarker study of its kind on the mainland. There are viagra no prescription but choose always the best. Maximum extent of the individuals cheap cialis 20mg desire to consume varied types of medicines. Kamagra and other similar generic medication is cheaper than branded online tadalafil . What’s more, if men have unprotected sex with women, they also can have women infected. order viagra without prescription The study demonstrated a high degree of CD95 ligand expression consistency between geographically diverse Chinese and Western glioblastoma multiforme patients. Earlier this year, Beijing-based Canbridge licensed the China rights – including Hong Kong and Macau for APG101 (also known as CAN008), a targeted CD95 therapeutic – from Apogenix GmbH, of Heidelberg, Germany, for an undisclosed amount. (See BioWorld Asia, July 22, 2015.)

Click here to read the full article.

Leave a Reply

Your email address will not be published. Required fields are marked *